Form 4: Ventyx Biosciences CFO Auster Reports Stock Transactions
SEC Form 4 Filing
Martin Auster, CFO of Ventyx Biosciences, reports the vesting and subsequent disposal of restricted stock units on March 28, 2024.
Summary
- On March 28, 2024, Martin Auster, the Chief Financial Officer of Ventyx Biosciences, Inc., had 4,531 restricted stock units (RSUs) vest.
- These RSUs were then disposed of at a price of $0.
- Following these transactions, Auster directly owns 13,594 derivative securities and 25,708 shares of common stock.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to executive compensation. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the transactions of company executives and their potential impact on the stock's price and investor confidence.
Stakeholder Impact
- The transaction could have a minor impact on shareholders due to the change in ownership reported by a key executive.
Key Dates
| Date | Description |
|---|---|
| 03/28/2023 | RSU Vesting Commencement Date |
| 03/28/2024 | Date of transaction: Vesting and disposal of RSUs |
| 03/29/2024 | Date of report filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.